US medicines agreement could restrict NHS recruitment by 10,000 posts

The NHS could afford around 10,000 fewer staff in 2028 because of the additional medicines spending promised under a UK-US trade agreement, according to analysis by the Nuffield Trust.

The health think tank stressed that its estimate does not mean 10,000 existing employees will necessarily lose their jobs. Instead, it suggests the NHS may be unable to expand its workforce by as much as it otherwise could, limiting efforts to fill vacancies and keep pace with growing demand.

Under the agreement, the UK committed to increasing spending on new branded medicines to 0.35% of gross domestic product by 2028. The Nuffield Trust estimates that meeting this commitment will require an additional £1.6 billion across the UK during that year.

Its modelling assumes that 59% of the extra cost would come from money that might otherwise have supported the NHS workforce, reflecting the proportion of current health spending directed towards employed and contracted staff. Other areas of NHS spending would still need to provide approximately £660 million.

Sally Gainsbury, senior policy analyst at the Nuffield Trust, said the agreement appeared to create a “major trade-off” for the health service. While higher medicines spending could give patients access to more treatments, she warned that the NHS may have to divert resources from existing services unless additional funding is provided.

The deal was intended to protect UK pharmaceutical exports from US tariffs while supporting access to innovative medicines and encouraging investment in Britain’s life-sciences sector. Changes linked to it have also increased the cost-effectiveness threshold used when assessing whether some new treatments should be made available through the NHS.

However, the Nuffield Trust said the full consequences remain difficult to assess because the Government has not published its impact assessment. The organisation has called for greater transparency over the expected costs, benefits and implications for frontline care.

With the NHS already facing significant workforce shortages, the warning highlights a central question surrounding the agreement: whether the cost of expanding access to new medicines will be met with additional funding or absorbed by services already under intense financial pressure.

Stay informed with the stories shaping health and social care.

Register with The Daily Round for the latest sector news, inspections & reports, wellbeing content, workforce insights, expert features and practical updates—delivered free to your inbox.